Science & Enterprise subscription

Follow us on Twitter

  • A new company developing treatments to relieve allergic reactions with reprogrammed antibodies began work and is ra… https://t.co/LFNVxych8d
    about 1 hour ago
  • New post on Science and Enterprise: New Allergy Biotech Launches, Raises $10M https://t.co/x5W0TwnCBu #Science #Business
    about 1 hour ago
  • Two companies and NIH are beginning a clinical trial of synthetic antibodies to both treat and prevent Covid-19 inf… https://t.co/LaUrUiRmhk
    about 20 hours ago
  • New post on Science and Enterprise: Trial Set for Covid-19 Antibodies in Long-Term Care https://t.co/tF0a7CDgGr #Science #Business
    about 20 hours ago
  • The numbers of vaccine candidates in development and clinical trials show modest but steady growth, now up to 157 a… https://t.co/AO2DxxTgF8
    about 1 day ago

Please share Science & Enterprise

Pharma Company, Institute Seek Alzheimer’s Targets

Illustration of brain (NIDA)

(National Institute of Drug Abuse)

Sanford-Burnham Medical Research Institute in La Jolla, California and Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI) in Titusville, New Jersey said today they formed a partnership to discover compounds for Alzheimer’s disease and other psychiatric disorders. Under the agreement, joint Sanford-Burnham and OMJPI teams will identify and validate new targets for drug discovery, leading to compounds suitable for further development by OMJPI.

OMJPI gains from the deal exclusive access for three years to a Sanford-Burnham’s scientists and translational research facilities  for discovering new approaches to treating patients neurological and psychiatric conditions. Sanford-Burnham will receive upfront and yearly access fees, funding of discovery research in the field, milestone payments, and royalties for successfully developed products. The parties did not reveal the amount of funding involved.

A joint steering committee will oversee the project, including a team funded by OMJPI in the Conrad Prebys Center for Chemical Genomics (CPCCG) at Sanford-Burnham. CPCCG is Sanford-Burnham’s screening facility established by National Institutes of Health as part of a national effort to accelerate the rate of commercialization of basic research by generating small molecule probes that can be used to develop a pipeline of drugs to treat unmet medical needs.

Read more: Partnership to Identify Targets for Neurological Diseases

*     *     *

1 comment to Pharma Company, Institute Seek Alzheimer’s Targets